| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SEASTAR MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11. | SeaStar Medical Holding Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | SeaStar Medical Holding Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Seastar Medical anticipates NEUTRALIZE-AKI enrollment completion by midyear 2027 while preparing modular PMA submissions | 3 | Seeking Alpha | ||
| 11.11. | Earnings Call: SeaStar Medical übertrifft Umsatzerwartungen im dritten Quartal 2026 - EPS verfehlt Prognose | 2 | Investing.com Deutsch | ||
| 11.11. | SeaStar Medical Holding Q3 2026 Earnings Call Transcript | 2 | Benzinga.com | ||
| 11.11. | SeaStar Medical Holding GAAP EPS of -$1.03 misses by $0.08, revenue of $0.64M beats by $0.14M | 1 | Seeking Alpha | ||
| 11.11. | SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates | 1 | GlobeNewswire (USA) | ||
| 04.11. | SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026 | 6 | GlobeNewswire (USA) | ||
| 03.11. | FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients | 3 | GlobeNewswire (USA) | ||
| 03.11. | SeaStar Medical Holding Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 22.10. | SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE SAVE Registry Analysis in Pediatric Sepsis-Associated AKI | 4 | GlobeNewswire (USA) | ||
| 14.10. | SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award | 2 | GlobeNewswire (USA) | ||
| 07.10. | FDA grants breakthrough device status to SeaStar for sepsis therapy | 2 | Investing.com | ||
| 07.10. | FDA erteilt Sepsis-Therapie von SeaStar den Status "Breakthrough Device" | 3 | Investing.com Deutsch | ||
| 07.10. | FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition | 218 | GlobeNewswire (Europe) | Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER... ► Artikel lesen | |
| 05.10. | SeaStar Medical Holding Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026 | 1 | GlobeNewswire (USA) | ||
| 01.10. | New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI) | 1 | GlobeNewswire (USA) | ||
| 29.09. | SeaStar Medical CMO to present at pediatric therapy conference | 1 | Investing.com | ||
| 24.09. | SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy | 2 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 51,38 | -0,77 % | Fresenius gewinnt eine neue Wachstumsstory | Fresenius hat den schwierigen Teil seiner Neuaufstellung offenbar weitgehend hinter sich gelassen. Der Gesundheitskonzern steigert seine Profitabilität, reduziert die finanzielle Belastung und hebt... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,600 | +2,40 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 42,960 | -1,96 % | Siemens-Aktie: Wie viel Luft hat die Dividende nach dem Healthineers-Abschied? | Siemens als Dividendenwert? Mit knapp 2 Prozent Rendite wirkt der Konzern eher wie ein Wachstumswert im Anzug. Doch die Ausschüttung klettert Jahr für Jahr, und jetzt trennt sich Siemens auch noch von... ► Artikel lesen | |
| GERRESHEIMER | 31,560 | -4,36 % | Gerresheimer: Was Anleger vor dem Jahresfinale prüfen sollten | ||
| THERMO FISHER | 612,80 | -2,39 % | 65% der untersuchten FDA-Rückschläge betrafen Produktionsstätten: Die unsichtbare Hürde für Lonza, Thermo Fisher und NeuroThera | ||
| TELADOC HEALTH | 6,872 | -3,37 % | Truist raises Teladoc stock price target to $9 on EBITDA outlook | ||
| STRATEC | 28,650 | +0,17 % | Stratec-Aktie: Sind 35 € ein realistisches Kursziel? | Die Stratec-Aktie konnte zuletzt wieder deutlich zulegen und notiert am Donnerstag aktuell bei 28,90 €. Gegenüber dem Tief im Juni bei etwa 17 € entspricht das einem Anstieg von rund +65%. Neben soliden... ► Artikel lesen | |
| HIMS & HERS HEALTH | 13,560 | -7,12 % | Hims & Hers Health, Inc: Hers launches free Metabolic Deep Dive to help show UK women what's really holding back their weight loss | Hers launches free Metabolic Deep Dive to help show UK women what's really holding back their weight loss
New YouGov research finds 61% of UK women are trying to lose weight, yet many are working... ► Artikel lesen | |
| BICO GROUP | 1,316 | -6,67 % | BICO Group AB reports Q3 results | ||
| M1 AESTHETICS | 13,500 | +1,50 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| EUROFINS SCIENTIFIC | 84,98 | +0,07 % | Eurofins Scientific SE: Weekly Report on Share Repurchases from 09th November to 13th November 2026 | Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument ... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,064 | +8,45 % | Sernova Biotherapeutics: 11,2 Millionen Dollar für die Fusion - und doch rutscht die Aktie | ||
| FAMICORD | 2,300 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.11.2026 | Das Instrument E36 CY0101162119 SED ENERGY HLDGS. DL 0,2 EQUITY wird cum Kapitalmassnahme gehandelt am 06.11.2026 und ex Kapitalmassnahme am 09.11.2026 The instrument E36 CY0101162119 SED ENERGY HLDGS.... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 38,950 | -0,57 % | Boston Scientific Corporation: Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes | MARLBOROUGH, Mass., Nov. 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) announced today that it has priced a public offering of $3,000,000,000 aggregate principal... ► Artikel lesen | |
| DEXCOM | 72,60 | -0,82 % | DexCom, Inc.: Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone | Opening ceremony attended by Minister for Public Expenditure, Infrastructure, Public Service Reform and Digitalisation, Jack Chambers, TD; Minister for Enterprise, Tourism and Employment, Peter... ► Artikel lesen |